#stemcellassay

As stated before, cell-based assays are tests that inform us of the effects of introducing a new substance into the cell. These effects can be of various kinds. Thus, cell-based assays test lots of variables like fluorescence, radioactivity, luminescence, etc. The different kinds of cell-based assays are listed below.

The report "

Stem Cell Assay Market

 by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021"The global stem cell assay market is expected to reach USD 1,363.3 Million by 2021 from USD 536.6 Million in 2016, at a CAGR of 20.5% from 2016 to 2021.

Browse 73 market data Tables and 93 Figures spread through 182 Pages and in-depth TOC on "Stem Cell Assay Market “

http://www.marketsandmarkets.com/Market-Reports/stem-cell-assay-market-47610330.html

Early buyers will receive 10% customization on This report.

 Market growth can be attributed to the high prevalence of chronic diseases, increasing investment in research related activities, and technological advancements. However, stringent regulatory policies and high cost of stem cell based therapies are major factors restraining the growth of this market.

In this report, the global stem cell assay market has been segmented based on type of assay, by kits, by detection, by instruments, by application, end-user, and region.

On the basis of type, the market has been segmented into viability/cytotoxicity, isolation & purification, cell identification, proliferation, differentiation, function and apoptosis. The viability/cytotoxicity segment is expected to account for the largest share of the market in 2016. The high growth in this segment is primarily attributed to the increasing focus of the pharmaceutical industries on drug screening which resulted in the increasing the demand for stem cell assays.

Based on kits, the stem cell assay market has been segmented into adult stem cell kits and human embryonic stem cell kits. The adult stem cell kits are further segmented into mesenchymal stem cell kits, induced pluripotent stem cell kits (IPSCs), hematopoietic stem cell kits, umbilical cord stem cell kits and neuronal stem cell kits. The adult stem cell kits segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment can be primarily attributed to the effectiveness of this type of kits in cell analysis.

Based on application, the global stem cell assay market is segmented into regenerative medicine & therapy development, drug discovery and development and clinical research. The regenerative medicine & therapy development segment is further segmented into orthopedic & musculoskeletal, spine, cardiovascular, oncology, central nervous system, dermatology, diabetes and others. The regenerative medicine & therapy development segment is projected to witness the highest growth rate during the forecast period due to the increase in incidences of chronic diseases which further leads to the increased demand for regenerative medicines.

The Sample Report For This Report@

http://www.marketsandmarkets.com/requestsample.asp?id=47610330

Geographically, the stem cell assay market is dominated by North America, followed by Europe, the Asia-Pacific region, and the Rest of the World (RoW). Growth in the North American region is primarily driven by the increasing incidence and prevalence of chronic diseases and increasing patient pool in North American countries.

The major players in the global stem cell assay market are GE Healthcare (U.K.), Promega Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Cell Biolabs, Inc. (U.S.), Hemogenix Inc. (U.S.), STEMCELL Technologies Inc. (CA), Bio-Rad Laboratories, Inc (U.S.), Bio-Techne Corporation (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Get The PDF Brochure For This Report@

http://www.marketsandmarkets.com/pdfdownload.asp?id=47610330

 About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

 Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

 MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.  

 Contact:

Mr. Rohan

MarketsandMarkets™

701 Pike Street

Suite 2175, Seattle,

WA 98101, United States

Tel: 1-888-600-6441